Streetbeat News

Regulatory

SPY

The Texas Services Sector Outlook for June improved to -8.2 compared to -17.3 in the previous month, indicating a recovery in the sector.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 2:32 pm

ALDX

Aldeyra Therapeutics announced positive top-line results from the Phase 2 clinical trial of ADX-629, an investigational drug for chronic cough. The trial achieved statistical significance for key secondary endpoints, and ADX-629 was well-tolerated with no safety concerns. Aldeyra plans to discuss the results with regulatory authorities and consider expanding clinical testing.

Portfolio Pulse from Vandana Singh

June 27, 2023 | 2:05 pm

SPY

The Richmond Manufacturing Index for June came in at -7, better than the estimated -10 and an improvement from the previous month's -15.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 2:05 pm

SPY

VGK

Belarus President Lukashenko confirmed that Wagner Group founder Prigozhin is in Belarus, according to Reuters citing Belta.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 1:43 pm

CODGF

CODYY

Saint-Gobain and its local unit face a lawsuit by India's antitrust authorities for anti-competitive practices. The company allegedly forced partners to exclusively buy glass from it or risk supply stoppage and manipulated its market position in the clear float glass products.

Portfolio Pulse from Lekha Gupta

June 27, 2023 | 1:14 pm

RHHBY

Roche has received FDA clearance for additional Alzheimer's disease cerebrospinal fluid assays, expanding its diagnostic capabilities.

Portfolio Pulse from Bill Haddad

June 27, 2023 | 1:06 pm

DRMA

Dermata Therapeutics has received FDA feedback on its DMT310 Phase 3 clinical development program for moderate-to-severe acne. The program will consist of two pivotal trials, STAR-1 and STAR-2, with the first patient enrollment planned for 2H 2023.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 1:04 pm

INVO

INVO Bioscience has received FDA clearance for the expanded use of its INVOcell device, now cleared for a 5-day incubation period. The supporting data shows improved patient outcomes, similar to IVF.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 1:02 pm

CARA

Cara Therapeutics has been granted U.S. Patent #11684674 for oral formulations of kappa opioid receptor agonists, which could potentially lead to new treatments for pain and pruritus.

Portfolio Pulse from Charles Gross

June 27, 2023 | 12:52 pm

AIM

AZN

AIM ImmunoTech has received approvals from the Netherlands to begin a Phase 1b/2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi for the treatment of pancreatic cancer. Patient enrollment is expected to commence before the end of 2023.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 12:47 pm